{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are currently recognized as the most common genetic cause of parkinsonism. Disease-associated mutations of LRRK2 tend to increase its kinase activity and thereby its toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to increased kinase activity and toxicity of the LRRK2 protein, which is relevant to the functional assay being described for the G2019S variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "A number of groups have recently generated Drosophila models of LRRK2 mutant-induced parkinsonism.",
          "judgment": "Yes",
          "reasoning": "The use of Drosophila models to study LRRK2 mutant-induced parkinsonism is a well-established approach in the field, thus making the assay applicable for modeling the disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper describes the generation of transgenic Drosophila over-expressing various human LRRK2 alleles, including the G2019S variant, and assesses late-onset loss of dopaminergic neurons, which serves as a valid instance of an assay for evaluating the pathogenicity of the G2019S variant."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "We found that transgenic flies harboring G2019S, Y1699C, or G2385R LRRK2 variant, but not the wild-type protein, exhibit late-onset loss of dopaminergic (DA) neurons in selected clusters that is accompanied by locomotion deficits.",
          "judgment": "Yes",
          "reasoning": "The functional assay results provide evidence that the G2019S variant contributes to DA neurodegeneration, supporting the pathogenicity of this variant.",
          "next_step_or_outcome": "Proceed to determine evidence strength"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G2019S variant in LRRK2 shows strong evidence of pathogenicity based on the functional assay results demonstrating late-onset loss of dopaminergic neurons and locomotion deficits in Drosophila models, consistent with the pathogenic mechanism of increased kinase activity and neurotoxicity."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are currently recognized as the most common genetic cause of parkinsonism. Disease-associated mutations of LRRK2 tend to increase its kinase activity and thereby its toxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to increased kinase activity and toxicity of the LRRK2 protein, which is relevant to the functional assay being described for the G2385R variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "A number of groups have recently generated Drosophila models of LRRK2 mutant-induced parkinsonism.",
          "judgment": "Yes",
          "reasoning": "The use of Drosophila models to study LRRK2 mutant-induced parkinsonism is a well-established approach in the field, thus making the assay applicable for modeling the disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper describes the generation of transgenic Drosophila over-expressing various human LRRK2 alleles, including the G2385R variant, and assesses late-onset loss of dopaminergic neurons, which serves as a valid instance of an assay for evaluating the pathogenicity of the G2385R variant."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Flies expressing the G2385R variant also display similar, age-dependent, pattern of degeneration as the G2019S LRRK2-expressing flies.",
          "judgment": "Yes",
          "reasoning": "The functional assay results provide evidence that the G2385R variant contributes to DA neurodegeneration, supporting the pathogenicity of this variant.",
          "next_step_or_outcome": "Proceed to determine evidence strength"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G2385R variant in LRRK2 shows strong evidence of pathogenicity based on the functional assay results demonstrating age-dependent pattern of degeneration similar to the G2019S variant in Drosophila models, consistent with the pathogenic mechanism of increased kinase activity and neurotoxicity."
    }
  ]
}